Achaogen — Investor Presentation (April 2016)
37 slides from Achaogen's investor presentation, Apr 7, 2016
Slide 1: Corporate Presentation
_ | x ACHAOGEN Corporate Presentation Nasdaq: AKAO April 2016
Slide 2: Forward Looking Statements
Forward Looking Statements EE EE This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective prod
Slide 3: Achaogen Inc.
Achaogen Inc. Achaogen is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. + Began operations in 2004 + Core Values + Market Cap, April 1: $50 million * S
Slide 4: Late Stage Company Developing Novel Antibacterial Medicines
Late Stage Company Developing Novel Antibacterial Medicines a Plazomicin: Superior potency against Carbapenem- Resistant Enterobacteriaceae (CRE) infections Differentiated Lead Product Single Phase 3 trial required for U.S. approval Clear Path to Market ® EPIC cUTI/AP LPI anticipated 2016, top-line
Slide 5: Achaogen Leadership Team
Achaogen Leadership Team Kenneth Hillan, MB, ChB President and Chief Executive Officer lan Friedland, MD Chief Medical Officer Blake Wise Chief Operating Officer Genentech cupist Locentis | backgroundin | drugdiscovery, c-actemea | developmentand Zeryn Sarpangal Vice President, Human Resources and C
Slide 6: Achaogen Pipeline Opportunity
_Achaogen Pipeline Opportunity EEE Product Candidate Discovery Preclinical Phase 1 Phase 2 Phase 3 Plazomicin EPIC (Evaluatir Additional Gram Negative Targets Fd * CRE carbapenem-resistant Enterobacteriaceae ACHAOGEN ~*MDR_ multi-drug resistance 6
Slide 7: Unmet Medical Need
Unmet Medical Need GHAOGEN’ _— : : Bj
Slide 8: Multi-Drug Resistant (MDR) Bacteria Spread Rapidly
Multi-Drug Resistant (MDR) Bacteria Spread Rapidly Rendering Traditional Therapies Less Effective 7005_ => Klebsiella pneumoniae (MDR = Resistant to 3rd-generation Cephalosporins, Fluoroquinolones and Laminoaiycosides) Escherichia coli (ESBL = represented by resistance to 3rd- generation Cephalospor
Slide 9: Prevalence of ESBL and CRE are High and Increasing
Prevalence of ESBL and CRE are High and Increasing; _. Mortality in CRE is up to 50% See ESBL+ Enterobacteriaceae by region (n=48,878; 2011-2013) % ofisolates + ESBL+ isolates represent pneumoniae (n=3,327), K oxytoce (n287),P. mirabilis(n=280), E coli(n=3,917), and other Enterobacteriaceae species
Slide 10: Need for New Treatments for Multi-Drug Resistant Infections is Critical
Need for New Treatments for Multi-Drug Resistant Infections is Critical a _—E—eee Multi-drug resistant (MDR) | [ ] Finca sPiceet} carpapenem Resistant ibioti -lactamase nterobacteriaceae Antibiotic Class producers (GRE) Aminoglycosides Fluoroquinolones Cephalosporins SKKX Carbapenems 3%} inactive vs
Slide 11: Projected Human and Economic Costs of Antimicrobial Resistance
Projected Human and Economic Costs of _ Antimicrobial Resistance are Significant eee Estimated Annual Rates of Major Causes of Death* La | Cadets TT Diarhoeal dsc | | & cx acces a | | | | | | | | | | ‘Antimicrobial resin | é Measles ' Cholera Tetanus J o 1 2 3 4 10 Annual Deaths (millions) m=Curent
Slide 12: Plazomicin Overview
Plazomicin Overview
Slide 13: Plazomicin: A Next Generation Aminoglycoside
Plazomicin: A Next Generation Aminoglycoside Being Developed for the Treatment of MDR Enterobacteriaceae + Unique: the only aminoglycoside engineered to overcome AMEs (aminoglycoside modifying enzymes) that inactivate existing aminoglycosides : AMEs co-travel with other resistance mechanisms, includ
Slide 14: Plazomicin Exhibits Superior In Vitro Potency Against CRE
Plazomicin Exhibits Superior /n Vitro Potency Against CRE Relative to Other Antibiotics SSS In vitro Activity vs. Clinical Isolates of CRE Compound Class Plazomi Aminoglycos! Gentamicin Aminoglycoside Amikacin Aminoglycoside 983 32 7 64 Ciprofloxacin Fluoroquinolone 822 8 8 Ceftazidime Cephalosporin
Slide 15: Clinical Cure and Microbiological Eradication Rates Similar in Phase 2 cUTI Study
Clinical Cure and Microbiological Eradication Rates Similar __to Active Comparator in Phase 2 cUTI Study % Patients with favorable Response 100% 90% 80% 70% 60% 71% Clinical Cure (MITT) Microbiological Eradication (ME) ® Plazomicin 10mg/kg m Plazomicin 15mg/kg © Levofloxacin 750mg MITT: modified int
Slide 16: Plazomicin Differentiated From Late Stage Competitors
Plazomicin Differentiated From Late Stage Competitors: Broad CRE Coverage, CRE Clinical Data in BSI and : Pneumonia, and Once/Day Dosing oe Indications Class Plazomicin / ta eal Aminoglycoside NIA ict Vv SY oT Vo ton, CRE:BSI& chaogen Rell HAP/VAP x Vv Label: cUTI, Avycaz/ (ceftazidime + 3x/day clAl
Slide 17: Beta-Lactam combinations and resistance quotes
‘[Beta-Lactam combinations] are important for treatment of serious gram-negative infections, but resistance is increasing. New B-lactamase inhibitor combination drugs in development have the potential to overcome some, but not all, of resistance from the most potent B- lactamases such as those found
Slide 18: Plazomicin Registration Pathway
Plazomicin Registration Pathway 18
Slide 19: Clear Registration Path Based on EPIC Study in cUTI
Clear Registration Path Based on EPIC Study in cUTI; Timeline Accelerated, Topline Data in Q117 2018 ae Sa, ¢ = - Registration Study 2016 Qi17 2H"17 LPI Topline NDA 2018 Data Submission LAUNCH & S y 4H17 Topline Data Include with EPIC NDA mare “MDR gram-negative infections are an increasing worldwid
Slide 20: Pivotal Phase 3 EPIC cUTI Study
Pivotal Phase 3 EPIC cUTI Study: Randomized, double blind comparator controlled with oral step-down option EE Plazomicin 15mg/kg lV Signs/ QD Primary Endpoint Microbiological symptoms of cUTI, including 71 N~530 AP Levofloxacin eradication + clinical cure Meropenem « — Single global Phase 3 trial fo
Slide 21: Phase 3 CARE CRE Study
Phase 3 CARE CRE Study Important clinical data in patients with CRE infections Cohort 1: BSI, HABP or VABP Plazomicin-based Presumed or Documented A regimen CRE Infection 4 Secondary Endpoints (Bloodstream Infection or a’ a i Pneumonia) ' Safety Colistin-based | ee ft . regimen = [> : Pharmacoeconom
Slide 22: Commercial Opportunity Overview
Commercial Opportunity Overview
Slide 23: Several Factors Drive Commercial Opportunity for Plazomicin
Several Factors Drive Commercial Opportunity for Plazomicin v Significant unmet need in a substantial and growing population of ieee Patients with MDR/CRE infections v Plazomicin is well-differentiated from current and emerging feed treatment options v U.S. market can be pursued with an efficient co
Slide 24: Estimated Million Days of Potential Opportunity for Plazomicin in CRE Infections
Estimated 2 Million Days of Potential Opportunity _for Plazomicin in CRE Infections Total Inpatients* Confirmed CRE Opportunity 12.0M 5-14 _ ~1MM Days of = fea: Days of Therapy Pneumonia = ~5MM Daysict Days of Therapy Therapy Sources: Decision Resources, Arlington Medical Resources, ~1.5MM primary l
Slide 25: Significant Growth Projected in CRE Population
Significant Growth Projected in CRE Population Hospital Treated Infections Projected Rise in Confirmed CRE 450,000 400,000 350,000 300,000 250,000 200,000 150,000 100,000 50,000 Population (US + EU-5) 1 Intra-Abdominal Infections =uTl = Pneumonia =BSI + Sepsis CRE Rate for Key Hospital-Treated Infec
Slide 26: Strong Physician Interest in Prescribing Plazomicin
Strong Physician Interest in Prescribing Plazomicin for Both Confirmed and Suspected CRE EE Confirmed CRE Suspected CRE Physician Market Share Estimates Physician Market Share Estimates 45% 45% 40% 40% 35% 35% 30% 30% 25% 25% 20% 20% 15% 15% 10% 10% 5% 5% 0% 0% cuTl BSI Pneumonia cUTl BSI Pneumonia
Slide 27: Approximately 70% of Plazomicin Use in CRE Anticipated to be Combination Use
Approximately 50 to 70% of Plazomicin Use in CRE is Anticipated to be Combination Use “a : Physician Adoption Estimates = Plazomicin combination with Avycaz @ Plazomicin combination ™Plazomicin single agent Percent of Plazomicin Use UTI BSI Pneumonia 2015 AKAO Quantitative Market Research Survey wit
Slide 28: Plazomicin Opportunity as Drug of Choice for Combo Therapy
Plazomicin has Opportunity to Take Unique Market _. Position as the Drug of Choice for Combo Therapy % * Only aminoglycoside engineered to overcome common resistance mechanisms * Positioned well for combination therapy - Add to empiric regimen to provide coverage vs. suspected CRE - Part of combinat
Slide 29: Plazomicin is Well-Positioned for Value-Based Pricing With cUTI Label
Plazomicin is Well-Positioned for Value-Based Pricing With cUTI Label Options No agents approved for CRE infections of any type and few drugs retain in vitro potency High Unmet Medical Need Limited use label supports usage in patients with highest unmet need CRE infections are associated with signif
Slide 30: Discovery Engine
Discovery Engine YY Preclinical programs targeting antibiotic resistant gram-negative bacterial infections ¢ LpxC inhibitor ¢ Antibody program
Slide 31: LpxC Inhibitors: Novel Mechanism of Action With Significant Potential
LpxC Inhibitors: Novel Mechanism of Action With Significant Potential Sa —E—EEEe ° New class of bactericidal antibiotics — LpxC is an essential enzyme required for outer membrane synthesis in gram-negative bacteria — Potent activity vs. P. aeruginosa — No pre-existing resistance ° Lead candidates cu
Slide 32: Therapeutic Antibody Program
Therapeutic Antibody Program ° Initial target candidate profile: Monotherapy treatment for serious gram-negative infections ° Hypothesis-driven approach focused on functionally important targets on the bacterial cell surface (targets not being disclosed + at this time) Y ° Potential benefits: A y —
Slide 33: Corporate Profile
Corporate Profile SACHAOGEN: _— : : 2,
Slide 34: Financial Snapshot
Financial Snapshot a ¢ IPO in March 2014 (NASDAQ: AKAO) ¢ Market capitalization as of April 1: $50 million ¢ Cash, cash equivalents, short-term investments at 12/31/15: $59 million * Non-dilutive funding opportunities — BARDA funding of $104 million for current plazomicin development * $27 million r
Slide 35: Anticipated Milestones 2016-2017
Anticipated Milestones 2016-2017 EPIC BARDA EPIC EPIC Enrollment Option 3 Fully Top-line Plazomicin Progress Award Enrolled Data NDA x e000 @eee CARE CARE Small Cohort 2 Top-line Molecule Data Data or mAb Published IND(s) 2016 2017 ACHAOGEN 36
Slide 36: Achaogen: Late Stage Company Developing Novel Antibacterial Medicines
Achaogen: Late Stage Company Developing Novel Antibacterial Medicines a Plazomicin: Superior potency against Carbapenem- Resistant Enterobacteriaceae (CRE) infections Differentiated Lead Product Single Phase 3 trial required for U.S. approval Clear Path to Market ® EPIC cUTI/AP LPI anticipated 2016,
Slide 37: Achaogen
<7 ACHAOGEN